2022-503119-40-00招募中3 期
Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 9
- 主要终点
- 1) To assess the efficacy of ixekizumab monotherapy versus MTX monotherapy in PsA dactylitis 2) To evaluate the degree of response by using the DACTOS score and the change of each sonographic detected elementary lesion of dactylitis in PsA participants
研究概览
简要总结
The main aims of the present study are: i. to assess the efficacy of ixekizumab monotherapy versus methotrexate monotherapy in PsA dactylitis; ii. to evaluate the degree of response by using the DACTOS score
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •adult age (≥ 18 years); - fulfilment of CASPAR criteria for PsA [2]; - naïve to csDMARDs and/or bDMARDs;; - presence of active dactylitis, diagnosed and evaluated at each centre through physical examination
排除标准
- •participation in another concurrent clinical intervention study within 30 days of randomization; - planned administration of live vaccines during the study period; - previous treatment with lymphocyte-depleting therapies or alkylating agents; - presence of one or more contraindication reported in datasheets of administered study drugs; - haemoglobin<9.0 g/dL, white-cell count<3.0×109/L, absolute neutrophil count<1.2×109/L, platelet count<100×109/L; - estimated glomerular filtration rate<40 ml/min (method of Cockcroft and Gault); - aspartate aminotransferase and/or alanine aminotransferase >1.5 times the upper normal range; - another autoimmune rheumatic disease except Sjogren’s syndrome; - recent, current, or chronic infection, including hepatitis B or hepatitis C infection or human immunodeficiency virus infection; - evidence of active, latent, or inadequately-treated Mycobacterium Tuberculosis infection; - a history of lymphoproliferative disorder; - major surgery within two weeks before starting study drugs, or having unhealed operation wounds; - history of cancer, except adequately treated, non-metastatic basal-cell or squamous-cell cancer of the skin or cervical carcinoma in situ; - Pregnant or lactating women (women of childbearing potential should have a negative test for HCG); - significant history of alcohol/drug abuse or addiction; - foreseeable inability to cooperate with given instructions and study procedures; - any condition precluding the administration of study drugs in compliance with datasheets indications; - any condition or laboratory parameter precluding the inclusion of the participant according to investigator.
结局指标
主要结局
1) To assess the efficacy of ixekizumab monotherapy versus MTX monotherapy in PsA dactylitis 2) To evaluate the degree of response by using the DACTOS score and the change of each sonographic detected elementary lesion of dactylitis in PsA participants
1) To assess the efficacy of ixekizumab monotherapy versus MTX monotherapy in PsA dactylitis 2) To evaluate the degree of response by using the DACTOS score and the change of each sonographic detected elementary lesion of dactylitis in PsA participants
次要结局
未报告次要终点
研究者
Annamaria Iagnocco
Scientific
Azienda Ospedaliera Ordine Mauriziano Di Torino
研究点 (9)
Loading locations...
相似试验
招募中
4 期
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic TherapyPlaque Psoriasis2023-509738-20-00AbbVie Deutschland GmbH & Co. KG150
尚未招募
不适用
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastatique non résécable : étude de phase 3 randomisée multicentrique en double aveugle.2023-507873-16-00Centre Hospitalier Regional Universitaire De Tours122
招募中
2 期
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy2022-502907-31-00Fondazione IRCCS Istituto Nazionale Dei Tumori20
招募中
3 期
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease2022-501645-70-00Abbvie Deutschland GmbH & Co. KG208
已完成
3 期
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)2023-504156-10-00Abbvie Deutschland GmbH & Co. KG72